Home About us Contact
|
Home About us Contact | ||
|
|
||
Hepatitis A Vaccination (hepatitis a + vaccination)
Selected AbstractsCost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis CHEPATOLOGY, Issue 4 2000R. Jake Jacobs No abstract is available for this article. [source] Cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis CHEPATOLOGY, Issue 4 2000Robert P. Myers M.D. No abstract is available for this article. [source] Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendationsJOURNAL OF VIRAL HEPATITIS, Issue 2008M. Ceyhan Summary., Hepatitis A is a worldwide vaccine-preventable infection. Recommendation of vaccination depends on the endemicity of the disease. The World Health Organization recommends universal hepatitis A vaccination in intermediate areas; however, there is no need of mass vaccination in high and low endemicity regions. Therefore, most of the countries are using a vaccination policy according to the endemicity characteristic representing the whole of the country. The endemicity of this infection varies due to sanitary and hygiene conditions and socioeconomic differences among the countries and in various regions of the same country. A sample of 1173 persons between the age of 0 and 91 years from nine randomly selected medical centres from five different geographical centres of Turkey were tested for the level of anti-hepatitis A virus (anti-HAV) immunoglobulin-G antibodies using an enzyme-linked immunosorbent assay. The overall prevalence of anti-HAV antibodies was 64.4% (1142/1173). While the rate of sero-positivity was over 80% in the 5,9 age group and more than 90% after 14 years of age in south-eastern and eastern regions, it was lower than 50% at the age of 5,9 years in central and western regions and remains under 80% in those areas. We conclude that the differences observed in HAV sero-positivity among various geographical regions in Turkey support a universal HAV immunization policy for children currently living in regions of intermediate endemicity. [source] Hepatitis A seroprevalence and its relationship with environmental factors in children of different age groups in Kahramanmaras, Eastern Mediterranean region of TurkeyJOURNAL OF VIRAL HEPATITIS, Issue 12 2007D. Kaya Summary., Hepatitis A infections are influenced by environmental and socioeconomic factors. Epidemiologic studies regarding hepatitis A virus (HAV) infection in Turkey have not previously examined these factors. We investigated HAV seroprevalence and its association with sociodemographic factors among children of various ages in the Eastern Mediterranean region of Turkey. The study included 1142 children (603 male and 539 female) between ages of 6 months and 18 years. Seropositivity in the whole group was 57.2%. HAV prevalence rates according to age groups were as follows: 35.5% in 6,23 months group, 19.2% in 2,5 years group, 74.3% in 6,10 years group, 83.0% in 11,14 years group, 92.8% in 15,18 years group. Risk factors that influenced seropositivity were; dense population, over-crowded families, excessive number of siblings, low socioeconomic status and low education of the mother. As HAV seroprevalence in children older than 6 years of age is high, we recommend hepatitis A vaccination in this region after the first year of life. [source] Hepatitis A and B vaccination and public healthJOURNAL OF VIRAL HEPATITIS, Issue 2007F. Blaine Hollinger Summary., The introduction and implementation of hepatitis B vaccination programmes in areas of high endemicity has been very stressful. However, this initial accomplishment has led to the reassessment of priorities in some countries which could undermine these early successes. Work still remains to be done to support and implement interventions that will bring us closer to the WHO goal and to the control of hepatitis B in the community at large. Hepatitis A vaccine strategy for immunizing toddlers is shifting to those countries with intermediate endemicity where increasing morbidity in adults is being observed. Accumulating evidence indicates that such programmes can result in impressive reductions in the incidence of hepatitis A by herd immunity. Monitoring of these populations to determine durability of protection will be important to avoid shifting the infection to the older age population, when symptoms are more likely to occur. National policies need to consider hepatitis A vaccination in the context of other public health priorities. [source] | ||||||||||